Erasmus Medical center

Phase [asc]	Trial	Trial Status	Site Status	Drug	NCT#
	GIST: Assessment of Tumor Mutations and TKI Plasma Exposure	Recruiting	Not yet activated	Imatinib + Sunitinib + Regorafenib	NCT02331914
1	(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors	Active, not recruiting	Closed	BLU-285	NCT02508532
1	A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]	Recruiting	Active	IDRX-42	NCT05489237
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Recruiting	Active, not recruiting	Bezuclastinib plus Sunitinib	NCT05208047
1/2	[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay)	Recruiting	Active	neoBOMB1	NCT03872778
			Active